Unveiling the traits of HER2-low breast cancer: a comparative analysis of IHC1+ vs IHC2+/ISH-negative subgroups – insights from a 3-year cohort study
Despite similar clinicopathological features, IHC2+/ISH- status was independently associated with lower pCR rates compared to IHC1+. These findings suggest that HER2-low subgroups may influence response to NACT and should be considered in multivariable prediction models, potentially informing stratified treatment approaches in the era of anti-HER2 ADCs.
Authors
- Paulina Lopes
- Ricardo Neto (ORCID: https://orcid.org/0000-0002-6144-0179)
- Gonçalo Fernandes (ORCID: https://orcid.org/0000-0002-3724-4944)
- Francisco Mascarenhas
- João Godinho (ORCID: https://orcid.org/0000-0003-2411-3993)
- Gil Prazeres
- Inês Margarido (ORCID: https://orcid.org/0009-0004-8716-0804)
- Catarina Pulido (ORCID: https://orcid.org/0000-0002-4313-7213)
- Mónica Nave (ORCID: https://orcid.org/0000-0001-5881-796X)
- José Luís Passos‐Coelho (ORCID: https://orcid.org/0000-0002-9458-8604)
- Jorge Correia (ORCID: https://orcid.org/0009-0004-2681-3250)
- Joana Albuquerque (ORCID: https://orcid.org/0000-0003-1989-3526)
- Ana Catarino
- Mody Abdoulaye Camara (ORCID: https://orcid.org/0009-0001-1487-2024)
- Isabel Estudante
Institutions
- Universidade Católica Portuguesa (PT)
- Hospital da Luz (PT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-07
- DOI
- https://doi.org/10.3389/fonc.2025.1675075
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00